Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, double-blind, placebo-controlled Phase 2 study to investigate the effic... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solut... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib M... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'N-Acetylcysteine or Erdosteine for Exacerbations of Chronic Obstructive Pulmonary Disease (NEX COP... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembr... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Eval... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Responses Against Paramyxoviruses in T cells with crOss Reactivity'. The following are the other r... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Effect of innate immune reprogramming by primary dengue on host response to secondary dengue'. The... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Validation of Gore Test in patients with Sphincteric Dyssynergia presenting with Dysfunctional Voi... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pemb... Read More